Evotec, Novo Nordisk
Evotec and Novo Nordisk in technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec SE (NASDAQ:EVO) entered a technology development partnership with Novo Nordisk A/S (NYSE:NVO) in cell therapy. Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline
While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.
Evotec and Novo Nordisk team up on cell therapies
Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo Nordisk will fund R&D at Evotec’s sites in Germany and Italy, with an option for exclusive rights to use the results in a specific therapeutic area.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26,
Novo Nordisk expands stem cell research arm with Evotec
Evotec has joined forces with Novo Nordisk to advance the clinical and commercial manufacturing of stem cell-based therapies.
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Pharmaceutical Technology3d
Evotec gets grant for inhibitors of epithelial sodium channel for treating diseases
Discover Evotec SE's groundbreaking patent for ENaC-inhibiting compounds, offering innovative treatments for respiratory, skin, and ocular diseases. Explore their potential!
Warburg Research Keeps Their Buy Rating on Evotec (0IRF)
In a report released today, Christian Ehmann from Warburg Research maintained a Buy rating on Evotec (0IRF – Research Report), with a ...
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - ...
devdiscourse1d
Global Pharma Developments and Challenges: A Comprehensive Summary
This summary covers key developments in the pharmaceutical sector, including Pfizer's initiatives in low-income nations, challenges faced by Canadian provinces in drug treatment policies, major trial ...
Evotec and Novo Nordisk forge technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors
Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable ...